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Abstract 
The aim of this study was to determine whether pre-treatment of human skin with the 
α1-adrenoceptor antagonist terazosin would block vasoconstrictor responses and 
axon-reflex vasodilatation to the α1-adrenoceptor agonist methoxamine. Drugs were 
administered by iontophoresis into the skin of the forearm of 15 healthy participants, 
and skin blood flow was monitored with a laser Doppler flow probe at the site of 
methoxamine iontophoresis (to monitor direct vasoconstrictor responses) or 5-10 mm 
from the site of methoxamine iontophoresis (to monitor axon-reflex vasodilatation). 
Experimental sites were pre-treated with terazosin (administered by iontophoresis for 
10 minutes at 200 µA), and the same current intensity was passed through 0.9% saline 
to control for the nonspecific effects of iontophoresis. Pre-treatment with terazosin 
blocked vasoconstrictor responses to increasing doses of methoxamine, and also 
blocked vasodilatation several mm from the site of terazosin and methoxamine 
administration. These findings support the view that α1-adrenoceptors play a role in 
generating axon-reflex vasodilatation, and thus might contribute to local vascular 
disturbances in acute and chronic inflammation. 
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Introduction 
  During noxious stimulation and tissue injury, inflammatory mediators such as 
hydrogen ions, bradykinin, prostaglandins and cytokines sensitize sensory afferents 
and initiate neurogenic inflammation (Richardson and Vasko, 2002). This response is 
coordinated by the sensory afferents that detect the noxious stimulus, and involves 
release of substance P and calcitonin gene-related peptide from the axonal network 
around the site of stimulation (Schmelz and Petersen, 2001). These neuropeptides 
increase vascular permeability and dilate blood vessels within the receptive field of 
the stimulated neuron (a process termed axon-reflex vasodilatation), thereby 
recruiting blood-borne immune cells and dispersing harmful substances.  
Under certain conditions, the sympathetic neurotransmitter noradrenaline may 
enhance axon-reflex vasodilatation. The most convincing evidence of this has come 
from laboratory studies of rats. For example, sympathectomy was found to inhibit the 
flare generated by intradermal injection of capsaicin in the rat hindlimb, whereas 
intra-arterial injection of the α1-adrenoceptor agonist phenylephrine restored the 
capsaicin-induced flare (Lin et al., 2003). In sympathetically-intact rats, blockade of 
peripheral α1-adrenoceptors with the α1-adrenceptor antagonist terazosin inhibited the 
flare to capsaicin. Similarly, sympathectomy and pre-treatment with terazosin 
inhibited sensitization of nociceptive C-fibres to intradermal injection of capsaicin in 
the rat hindpaw, whereas intra-arterial injection of noradrenaline restored the 
capsaicin-induced sensitization after sympathectomy (Ren et al., 2005). These 
findings are consistent with reports that sympathectomy inhibits behavioural signs of 
pain in certain animal models of inflammatory and neuropathic pain (Kinnman and 
Levine 1995; Kim et al., 1993; Shir and Seltzer, 1991; Xie et al., 2001). Conversely, 
α-adrenergic agonists evoke nociceptive discharge and pain in animals after nerve   4 
injury and inflammation (Ali et al., 1999; Nam et al., 2000; Dogrul et al., 2006), and 
in experimental and clinical studies in humans (Torebjork et al., 1995; Fuchs et al., 
2001; Mailis-Gagnon and Bennett, 2004; Jorum et al., 2007; Drummond, 2009).  
Despite such findings, it has been assumed that sympathetic and nociceptive 
fibres do not interact directly under physiological conditions in human skin, as 
intradermal injection of noradrenaline or delivery through microdialysis fibres is 
painless and does not evoke axon-reflex vasodilatation (Zahn et al., 2004). 
Nevertheless, intradermal microdialysis of noradrenaline was found to decrease the 
temperature threshold of axon-reflex vasodilatation to local heat in healthy humans, 
and sympathetic blockade attenuated this response (Houghton et al., 2006; Hodges et 
al., 2008). Furthermore, pre-treatment of the skin with local anaesthetic agent blocked 
the flare produced by noradrenaline when it was introduced into the skin by 
iontophoresis (Drummond and Lipnicki, 1999). Together, these findings imply that 
noradrenaline facilitates axon-reflex vasodilatation initiated by heat or iontophoretic 
currents in humans, and thus might contribute to axon-reflex vasodilatation evoked by 
inflammatory mediators after nerve or tissue injury.  
In rats, the adrenergic component of axon-reflex vasodilatation to capsaicin is 
mediated by α1-adrenoceptors (Lin et al., 2003) but whether this also applies in 
humans is uncertain because mechanisms of neurogenic inflammation differ between 
rat and human skin (Schmelz and Petersen, 2001; Sauerstein et al., 2000). Thus, the 
aim of the present study was to determine whether α1-adrenoceptors also mediate 
axon-reflex vasodilatation in healthy human subjects. In particular, the aim was to 
establish whether prior administration of the α1-antagonist terazosin would block 
axon-reflex vasodilatation to the α1-agonist methoxamine. If so, this would support   5 
the view that α1-adrenoceptors play an important role in neurogenic inflammation in 
humans.  
Method 
Subjects 
  The sample consisted of 15 healthy volunteers (4 men and 11 women aged 
between 18 and 47 years) who were not taking prescription medication for any 
medical condition. They each provided informed consent for the procedures, which 
were approved by the Murdoch University Human Research Ethics Committee. 
Procedures  
The experiments were carried out in a temperature-controlled laboratory 
maintained at 22 + 1
oC. The first step in each experiment was to introduce terazosin 
into the skin to block α1-adrenoceptors. To determine whether the terazosin blockade 
was successful, vasoconstrictor responses to incremental doses of methoxamine were 
examined at terazosin-pretreated and control sites. Axon-reflex vasodilatation to 
methoxamine was examined adjacent to the site of terazosin pre-treatment and 
methoxamine administration in the final seven participants. 
Pre-treatment with terazosin. Perspex iontophoresis capsules with an internal 
chamber diameter of 20 mm were attached with adhesive washers to the dorsal aspect 
of the left and right forearms, and 3 cm x 5 cm silver plates that acted as cathodes 
were attached to the wrists. Cotton swabs soaked with 0.9% saline were placed under 
the cathodes to enhance electrical contact with the skin. To ensure that the capsules 
adhered firmly and that good electrical contact was made, the forearm sites were 
shaved, if necessary, and cleaned with an isopropyl alcohol swab. Care was taken not 
to touch the skin with the razor while the hair was being removed. The perspex 
chambers were filled with a conducting medium (0.9% saline-control in one chamber   6 
and 10 mM terazosin hydrochloride in the other; Sigma, Sydney, Australia) and 
anodal currents of 0.2 mA were passed through the solutions to repel positively 
changed ions into the skin for 10 minutes (Drummond, 2002).  
Effect of the terazosin pre-treatment on vasoconstrictor responses to 
methoxamine (Figure 1A). Purpose-built iontophoresis capsules placed over the 
treated sites in the forearms were maintained at 40
oC to facilitate laser Doppler 
detection of cutaneous vasoconstriction (Lipnicki and Drummond, 2001). The 
capsules had an internal chamber diameter of 10 mm. The wide surface area probe of 
a Moor Instruments MBF3D laser Doppler flowmeter (Axminster, England) was 
inserted into the roof of the chamber several mm above the skin to monitor vasomotor 
responses at sites of drug entry. A solution of 10 mM methoxamine hydrochloride 
(Sigma, Sydney, Australia) was prepared on the day of the experiment with de-
ionized water. The chamber beneath the flowmeter probe was filled with the 
mexthoxamine solution through a stainless steel inlet tube. After 10 minutes of skin 
heating, a 5 µA anodal current was directed through the drug solution for 60 seconds 
to introduce positively-charged methoxamine ions into the skin. Skin blood flow was 
monitored during the iontophoresis and for another four minutes afterwards at the 
terazosin-pretreated and control sites. The same procedure was repeated at currents of 
10 µA through to 320 µA, doubling the current intensity after each step. As current 
duration was held constant at 60 seconds, the dose of methoxamine introduced into 
the skin was proportional to the current intensity. Cathodes on the wrists completed 
the electrical circuits. 
Effect of the terazosin pre-treatment on axon reflex vasodilatation to 
methoxamine. In the final seven participants, additional sites on the forearms were 
pre-treated with terazosin and 0.9% saline (control). The pre-treatment procedures   7 
were similar to those described above except that a central region of skin, 10 mm in 
diameter, was protected from the drug solution by a thick smear of petroleum jelly 
(Vaseline) (Figure 1B). Treated skin generally flushed after the iontophoresis of 
terazosin whereas the central region remained pale. After the pre-treatment, the 
petroleum jelly was removed and the subject rested quietly for 10 minutes to allow 
nonspecific vasomotor responses to the pre-treatment to subside. Iontophoresis 
capsules with a ring-shaped drug solution chamber (inner diameter 15 mm and outer 
diameter 19 mm) were then attached to the prepared sites and filled with 10 mM 
methoxamine solution. Adhesive tape was used to form a waterproof seal on each side 
of the drug solution chamber. The capsules were maintained at 32
oC (i.e., below the 
threshold for local heat-evoked vasodilatation) throughout the methoxamine 
iontophoreses that ranged in current strength from 5 µA to 320 µA, as described 
above. During each iontophoresis, positively-charged methoxamine ions were 
repelled away from the anode into the underlying skin for 60 seconds, followed by a 
4-minute period of vascular monitoring. Skin blood flow was detected with a wide 
surface area laser Doppler flow probe positioned in the centre of the ring described by 
the iontophoresis chamber, 5-10 mm from the site of methoxamine administration 
over skin that had been covered with petroleum jelly during the pre-treatment (Figure 
1B).  
Data reduction and statistical approach 
  Skin blood flow was averaged for 1-2 minutes before the first iontophoresis to 
establish a baseline. As responses generally began during the 1-minute period of 
iontophoresis and peaked during the subsequent 4-minute period of monitoring, the 
mean response over the full 5-minute period was calculated. Blood flow was 
measured both in terms of mean flux (the low-frequency component of the signal   8 
reflecting tissue perfusion to a depth of 1-2 mm) and the amplitude of the high 
frequency pulsatile waveform (representing the beat-to-beat difference between 
arterial inflow and venous outflow). As skin blood flow was recorded in arbitrary 
rather than absolute units, responses were expressed as the percent change from levels 
at baseline. 
  Differences in response to methoxamine at the terazosin-treated and control 
sites were investigated in Drug Treatment (terazosin, control) x Dose (the seven 
current intensities ranging from 5 µA to 320 µA) repeated measures analyses of 
variance. Where appropriate, the Greenhouse-Geisser epsilon was used to adjust the 
degrees of freedom to correct for violations of the sphericity assumption. Differences 
in blood flow between treated and control sites at baseline were investigated with 
Student’s paired t-tests.  
Results 
  At baseline, neither mean flux nor pulse amplitude differed between the 
terazosin-treated and control sites in skin heated to 40
oC, although values were 
substantially higher in heated than unheated skin (Figure 2). Similarly, blood flow did 
not differ significantly between control sites and sites that had been covered with 
petroleum jelly during the terazosin pre-treatment. 
  The terazosin pre-treatment blocked vasoconstriction to methoxamine (Figure 
3). In particular, the Drug Treatment x Dose interaction was significant both for mean 
flux [F(1.6,22.7) = 3.99, p<0.05] (Figure 3A) and pulse amplitude [F(2.2,31.1) = 3.50, 
p<0.05] (Figure 3B), due to divergent responses between the treated and control sites  
at higher doses of methoxamine. 
  Similarly, the terazosin pre-treatment blocked signs of axon-reflex 
vasodilatation at higher doses of methoxamine (Figure 4). Again, the Drug Treatment   9 
x Dose interaction was significant both for mean flux [F(1.2,7.4) = 5.36, p<0.05] 
(Figure 4A) and pulse amplitude [F(1.7,10.3) = 8.90, p<0.01] (Figure 4B). 
Discussion 
Pre-treatment with the α1-antagonist terazosin blocked the vasoconstrictor 
response to the α1-agonist methoxamine, indicating that the terazosin blockade was 
successful. The terazosin pre-treatment also blocked vasodilatation several mm from 
the site of methoxamine administration. Effects were detected not only for mean 
tissue perfusion (reflected by changes in flux) but also for pulsatile flow (reflected by 
the amplitude of beat-to-beat pulsations). These findings support the view that 
stimulation of α-adrenoceptors may play a role in generating the axon-reflex 
vasodilatation that accompanies acute and chronic inflammation not only in rats (Lin 
et al., 2003) but also in humans (Drummond and Lipnicki, 1999; Houghton et al., 
2006; Hodges et al., 2008). 
Adrenergic stimulation of sensory afferents   
Although the means by which adrenergic agents affect axon reflex 
vasodilatation is uncertain, some findings suggest that direct stimulation of α1-
adrenoceptors on neural membranes contributes to antidromic neuronal discharge and 
axon-reflex vasodilatation. Messenger RNA (mRNA) for α1A-, α1B- and α2C-
adrenoceptors has been demonstrated within rat dorsal root ganglion neurons 
(Nicholson et al., 2005), and α1-adrenoceptor mRNA increased in the dorsal root 
ganglia of rats after spinal nerve ligation and sciatic nerve transection (Xie et al., 
2001; Maruo et al., 2006) and in rats with streptozotocin-induced diabetic neuropathy 
(Lee et al., 2000). At the physiological level, the α1-agonist phenylephrine was found 
to mobilize intracellular calcium in cultured dorsal root ganglion cells, and to liberate   10 
substance P from the distal terminals of nociceptive afferents in the urinary bladder 
(Trevisani et al., 2007).  
Other data suggest that adrenergic agents stimulate the release of intermediary 
agents which excite nociceptive afferents. For example, phenylephrine was found to 
increase the secretion of nerve growth factor, a potent nociceptive agent, from 
cultured vascular smooth muscle (Tuttle et al., 1993), and to facilitate the nociceptive 
effects of adenosine triphosphate (Meisner et al., 2007). In the rat kidney, increases in 
renal sympathetic nerve activity were associated with increases in afferent renal nerve 
activity; in particular, noradrenaline acted via α1-adrenoceptors to increase the 
synthesis and release of prostaglandin E2 which, in turn, liberated substance P from 
nociceptive afferents (Kopp et al., 2007).  
Although the studies reviewed above were carried out on rats rather than 
humans, it is tempting to speculate that direct stimulation of neural α1-adrenoceptors 
or the release of intermediary agents such as prostaglandin E2 evoked axon reflexes to 
methoxamine in the present study. 
Role of inflammation   
Iontophoretic currents induce an inflammatory response in human skin 
(Grossmann et al., 1995) which is mediated at the anode by prostaglandin synthesis 
(Tartas et al., 2005). However, current-evoked prostaglandin production does not 
account entirely for axon-reflex vasodilatation to methoxamine, because the response 
was profoundly inhibited by pre-treatment with the α1-antagonist terazosin in the 
present study. The inflammatory mediators released by iontophoretic currents may 
disrupt the blood-nerve barrier, thereby increasing access to protected α1-
adrenoceptors in cutaneous nerve fascicles (Drummond, 1998). This could explain 
why the iontophoresis of adrenergic agonists evokes axon-reflex vasodilatation   11 
(Drummond and Lipnicki, 1999) whereas administration via intradermal microdialysis 
fibres does not (Zahn et al., 2004). 
Clinical implications 
      Although neurogenic inflammation is primarily protective, an abnormal 
excitability of this response could sensitize nociceptive afferents and promote chronic 
inflammation (Peters et al., 2006; Cunha et al., 2008). The present findings suggest 
that α1-adrenoceptors contribute to this process by evoking axon-reflex vasodilatation. 
During chronic inflammation, increased access to neural α1-adrenoceptors could 
establish a vicious circle between sympathetic neural discharge, neurogenic 
inflammation and pain. This might be important in genitourinary tract disorders 
(Trevisani et al., 2007) and in conditions such as complex regional pain syndrome, 
which is characterized by elevated levels of inflammatory mediators, enhanced axon-
reflex vasodilatation and signs of adrenergic supersensitivity in the affected limb 
(Schinkel et al., 2006; Wesseldijk et al., 2008; Weber et al., 2001; Birklein and 
Schmelz, 2008; Drummond et al., 1996; Arnold et al., 1993; Chemali et al. 2001; 
Jorum et al., 2007; Gibbs et al., 2008).    12 
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Figure legends 
Figure 1. A. To investigate the effect of terazosin pre-treatment on vasoconstrictor 
responses to methoxamine, terazosin (or saline control) was introduced into a 20 mm 
diameter circle of skin, followed by methoxamine in a 10 mm diameter circle at the 
centre of the pre-treated site. The skin was heated to 40
oC, and skin blood flow was 
measured from the central methoxamine-treated site with a laser Doppler flow probe. 
B. To investigate the effect of terazosin pre-treatment on axon-reflex vasodilatation to 
methoxamine, terazosin (or saline control) was introduced into a ring of skin (outer 
diameter 20 mm and inner diameter 10 mm). The central region was covered with 
petroleum jelly to insulate against passage of the iontophoretic current. Methoxamine 
was then administered in a ring at the site of terazosin or saline pre-treatment (outer 
diameter 19 mm and inner diameter 15 mm). Skin blood flow was measured from the 
central untreated site with a laser Doppler flow probe.   
Figure 2. Skin blood flow (+ S.E.) at baseline in skin maintained at 32
oC or 40
oC. 
Neither mean flux (A) nor pulse amplitude (B) differed significantly between the 
control site and the site of α1-blockade in heated skin, or between control sites and 
sites that had been covered with petroleum jelly during the terazosin pre-treatment 
(unheated sites). 
Figure 3. Change in skin blood flow (+ S.E.) after the iontophoresis of methoxamine 
at sites pre-treated with the α1-antagonist terazosin or 0.9% saline-control (see Figure 
1A). The dose of methoxamine introduced into the skin was proportional to the 
iontophoresis current (measured in µA). Pre-treatment with terazosin blocked 
decreases in mean flux (A) and pulse amplitude (B) at higher doses of methoxamine 
(* difference between control and terazosin pre-treated site statistically significant, 
p<0.05). Skin blood flow increased above baseline at the terazosin-treated site after   20 
low doses of methoxamine, and decreased below baseline at the control site after high 
doses of methoxamine (# difference from baseline statistically significant, p<0.05). 
Figure 4. Change in skin blood flow (+ S.E.) in the central untreated region after the 
iontophoresis of methoxamine in skin pre-treated with the α1-antagonist terazosin or 
0.9% saline-control (see Figure 1B). Skin blood flow increased at both sites after the 
iontophoresis of methoxamine (# difference from baseline statistically significant, 
p<0.05). However, pre-treatment with terazosin inhibited increases in mean flux (A) 
and pulse amplitude (B) at higher doses of methoxamine (* difference between 
control and terazosin pre-treated site statistically significant, p<0.05).   21   22 
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